Insys Therapeutics

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.
Company Growth (employees)
Type
Public
HQ
Chandler, US
Founded
1998
Size (employees)
423 (est)
Insys Therapeutics was founded in 1998 and is headquartered in Chandler, US

Key People/Management at Insys Therapeutics

Michael L. Babich

Michael L. Babich

CEO
Andrew Long

Andrew Long

Chief Financial Officer
Larry Dillaha

Larry Dillaha

CMO

Insys Therapeutics Office Locations

Insys Therapeutics has an office in Chandler
Chandler, US (HQ)
444 S Ellis Rd

Insys Therapeutics Financials and Metrics

Insys Therapeutics Financials

Insys Therapeutics's revenue was reported to be $242.3 m in FY, 2016
USD

Revenue (Q3, 2017)

30.7 m

Gross profit (Q3, 2017)

23.2 m

Gross profit margin (Q3, 2017), %

76%

Net income (Q3, 2017)

(166.3 m)

EBIT (Q3, 2017)

(175.7 m)

Market capitalization (13-Dec-2017)

454 m

Cash (30-Sep-2017)

35.8 m
Insys Therapeutics's current market capitalization is $454 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

99.3 m222.1 m330.8 m242.3 m

Revenue growth, %

124%49%(27%)

Cost of goods sold

12.7 m28.9 m25.4 m

Gross profit

86.6 m301.9 m216.9 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

29.2 m41.6 m55.7 m58.3 m70.8 m77.6 m91.3 m62 m67.1 m55.2 m36 m42.6 m30.7 m

Cost of goods sold

3.1 m4.8 m6.6 m5.4 m6.4 m8.3 m7.7 m4.6 m6.3 m4.7 m4.6 m3.9 m7.5 m

Gross profit

26.1 m36.9 m49.1 m52.9 m64.4 m69.3 m83.6 m57.3 m60.8 m50.5 m31.3 m38.7 m23.2 m

Gross profit Margin, %

89%89%88%91%91%89%92%93%91%92%87%91%76%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

45.4 m58.1 m79.5 m104.6 m

Inventories

14.5 m34.8 m41.7 m21.7 m

Current Assets

82.2 m151 m253.2 m231 m

PP&E

10.1 m38.4 m43.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

31.3 m40 m46.1 m47.4 m70.1 m74 m94 m73.8 m69.3 m93.5 m68.4 m49.8 m35.8 m

Accounts Receivable

12.4 m19.1 m

Inventories

11.7 m19.4 m24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m21.3 m20 m18.4 m

Current Assets

57.7 m91.3 m102.2 m128.7 m182.1 m198.2 m236.6 m220.8 m234 m235.2 m196.9 m197.2 m179.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

40.4 m58.5 m7.6 m

Depreciation and Amortization

1.8 m2.5 m5.3 m6.2 m

Accounts Receivable

(13 m)(10 m)(22 m)26.6 m

Inventories

(7.4 m)(20 m)(6.9 m)15 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

7.7 m9.5 m11.5 m8 m7.3 m26.1 m2.4 m4.4 m190 k(6.5 m)

Inventories

24.7 m31.4 m35.2 m35.6 m39.4 m32.2 m29.2 m28 m

Accounts Payable

15.1 m24.5 m36.6 m30.6 m24.2 m25.7 m22.2 m17.5 m28.2 m
USDY, 2017

Revenue/Employee

72.5 k

Financial Leverage

3 x
Show all financial metrics

Insys Therapeutics Market Value History

Insys Therapeutics Median Salaries

Source: 24 public H-1B filings from Insys Therapeutics

Insys Therapeutics's Web-traffic and Trends

Insys Therapeutics Company Life and Culture

You may also be interested in